Cesca Therapeutics Inc (KOOL) - Product Pipeline Analysis, 2017 Update

Summary

Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device division, ThermoGenesis Corp. offers the AutoXpress platform for automated clinical biobanking. The company is also developing CAR-TXpress platform for bio-manufacturing which find applications in immuno-oncology therapeutics. The company markets its products to patients, physician and partners in three target markets, namely, cellular therapeutics, medical/diagnostic device development and commercialization, and cell manufacturing and banking. Cesca is headquartered in Rancho Cordova, California, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cesca Therapeutics Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cesca Therapeutics Inc Company Overview 6
Cesca Therapeutics Inc Company Snapshot 6
Cesca Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview 7
Cesca Therapeutics Inc Pipeline Analysis Overview 9
Business Description 9
Cesca Therapeutics Inc - Key Facts 9
Cesca Therapeutics Inc - Major Products and Services 10
Cesca Therapeutics Inc Pipeline Products by Development Stage 11
Cesca Therapeutics Inc Ongoing Clinical Trials by Trial Status 13
Cesca Therapeutics Inc Pipeline Products Overview 15
AdiposePRO 500 15
AdiposePRO 500 Product Overview 15
AdiposePRO 60 16
AdiposePRO 60 Product Overview 16
CellWerks - ABO Mismatch 17
CellWerks - ABO Mismatch Product Overview 17
CellWerks - Haplo-identical 18
CellWerks - Haplo-identical Product Overview 18
CellWerks BMT 19
CellWerks BMT Product Overview 19
HarvestPRO Bone Marrow Collection Set 20
HarvestPRO Bone Marrow Collection Set Product Overview 20
RecoveryPRO Cord Blood Collection System 21
RecoveryPRO Cord Blood Collection System Product Overview 21
SurgWerks - AVN 22
SurgWerks - AVN Product Overview 22
SurgWerks - Ischemic Stroke 23
SurgWerks - Ischemic Stroke Product Overview 23
SurgWerks - Non-Healing Ulcers 24
SurgWerks - Non-Healing Ulcers Product Overview 24
SurgWerks - Non-Union Fractures 25
SurgWerks - Non-Union Fractures Product Overview 25
SurgWerks - Osteoarthritis 26
SurgWerks - Osteoarthritis Product Overview 26
SurgWerks - SF 27
SurgWerks - SF Product Overview 27
SurgWerks AMI Kit 28
SurgWerks AMI Kit Product Overview 28
SurgWerks AMI Kit Clinical Trial 29
SURGWERKS-CLI Therapy Kit - Intra-arterial 30
SURGWERKS-CLI Therapy Kit - Intra-arterial Product Overview 30
SURGWERKS-CLI Therapy Kit - Intra-Muscular 31
SURGWERKS-CLI Therapy Kit - Intra-Muscular Product Overview 31
SURGWERKS-CLI Therapy Kit - Intra-Muscular Clinical Trial 32
SynGen CellWashPRO 33
SynGen CellWashPRO Product Overview 33
VXP System 34
VXP System Product Overview 34
VXP System Clinical Trial 35
Cesca Therapeutics Inc - Key Competitors 36
Cesca Therapeutics Inc - Key Employees 37
Cesca Therapeutics Inc - Key Employee Biographies 38
Cesca Therapeutics Inc - Locations And Subsidiaries 39
Head Office 39
Other Locations & Subsidiaries 39
Recent Developments 40
Cesca Therapeutics Inc, Recent Developments 40
Sep 19, 2017: Cesca Therapeutics Announces Fiscal Year 2017 Financial and Operating Results and Provides Corporate Update 40
Aug 24, 2017: Cesca Therapeutics Announces International Distribution Agreement With Boyalife WSN 41
May 11, 2017: Cesca Therapeutics Announces Fiscal Third Quarter and Nine Month 2017 Financial and Operating Results and Provides Corporate Update 41
May 02, 2017: Cesca to Exhibit BioArchive System At The 25th International Society For Cellular Therapy Annual Meeting 42
May 02, 2017: Cesca to Exhibit At The 25th International Society For Cellular Therapy (ISCT) Annual Meeting 42
Apr 03, 2017: Cesca Therapeutics Announces Senior Management Promotions 42
Mar 20, 2017: Cesca CLI Feasibility Study Published in Peer-Reviewed Journal 43
Feb 28, 2017: Cesca Therapeutics Strengthens Leadership Team and Board of Directors 43
Feb 13, 2017: Cesca Therapeutics Reports Second Quarter Fiscal 2017 Financial Results and Provides Business Update 44
Jan 17, 2017: Cesca Therapeutics Appoints Dr. Joseph Thomis to Its Board of Directors 44
Appendix 46
Methodology 46
About GlobalData 48
Contact Us 48
Disclaimer 49

List Of Tables


Cesca Therapeutics Inc Pipeline Products and Ongoing Clinical Trials Overview 7
Cesca Therapeutics Inc Pipeline Products by Equipment Type 7
Cesca Therapeutics Inc Pipeline Products by Indication 8
Cesca Therapeutics Inc Ongoing Clinical Trials by Trial Status 8
Cesca Therapeutics Inc, Key Facts 9
Cesca Therapeutics Inc, Major Products and Services 10
Cesca Therapeutics Inc Number of Pipeline Products by Development Stage 11
Cesca Therapeutics Inc Pipeline Products Summary by Development Stage 12
Cesca Therapeutics Inc Ongoing Clinical Trials by Trial Status 13
Cesca Therapeutics Inc Ongoing Clinical Trials Summary 14
AdiposePRO 500 - Product Status 15
AdiposePRO 500 - Product Description 15
AdiposePRO 60 - Product Status 16
AdiposePRO 60 - Product Description 16
CellWerks - ABO Mismatch - Product Status 17
CellWerks - ABO Mismatch - Product Description 17
CellWerks - Haplo-identical - Product Status 18
CellWerks - Haplo-identical - Product Description 18
CellWerks BMT - Product Status 19
CellWerks BMT - Product Description 19
HarvestPRO Bone Marrow Collection Set - Product Status 20
HarvestPRO Bone Marrow Collection Set - Product Description 20
RecoveryPRO Cord Blood Collection System - Product Status 21
RecoveryPRO Cord Blood Collection System - Product Description 21
SurgWerks - AVN - Product Status 22
SurgWerks - AVN - Product Description 22
SurgWerks - Ischemic Stroke - Product Status 23
SurgWerks - Ischemic Stroke - Product Description 23
SurgWerks - Non-Healing Ulcers - Product Status 24
SurgWerks - Non-Healing Ulcers - Product Description 24
SurgWerks - Non-Union Fractures - Product Status 25
SurgWerks - Non-Union Fractures - Product Description 25
SurgWerks - Osteoarthritis - Product Status 26
SurgWerks - Osteoarthritis - Product Description 26
SurgWerks - SF - Product Status 27
SurgWerks - SF - Product Description 27
SurgWerks AMI Kit - Product Status 28
SurgWerks AMI Kit - Product Description 28
SurgWerks AMI Kit - Assessment of Safety of SurgWerks-AMI and VXP System for ST- Elevated Myocardial Infarction (STEMI) Caused Left Ventricle Ejection Fraction (LVEF) and Acute Myocardial Infarction (AMI) 29
SurgWerks AMI Kit - Safety and Effectiveness of the SurgWerks-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-reconstructable Critical Limb Ischemia Patients 29
SURGWERKS-CLI Therapy Kit - Intra-arterial - Product Status 30
SURGWERKS-CLI Therapy Kit - Intra-arterial - Product Description 30
SURGWERKS-CLI Therapy Kit - Intra-Muscular - Product Status 31
SURGWERKS-CLI Therapy Kit - Intra-Muscular - Product Description 31
SURGWERKS-CLI Therapy Kit - Intra-Muscular - Safety and Effectiveness of the SurgWerks-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-reconstructable Critical Limb Ischemia Patients 32
SynGen CellWashPRO - Product Status 33
SynGen CellWashPRO - Product Description 33
VXP System - Product Status 34
VXP System - Product Description 34
VXP System - Assessment of Safety of SurgWerks-AMI and VXP System for ST- Elevated Myocardial Infarction (STEMI) Caused Left Ventricle Ejection Fraction (LVEF) and Acute Myocardial Infarction (AMI) 35
VXP System - Safety and Effectiveness of the SurgWerks-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-reconstructable Critical Limb Ischemia Patients 35
Cesca Therapeutics Inc, Key Employees 37
Cesca Therapeutics Inc, Key Employee Biographies 38
Cesca Therapeutics Inc, Other Locations 39
Cesca Therapeutics Inc, Subsidiaries 39
Glossary 47

List Of Figures


Cesca Therapeutics Inc Pipeline Products by Equipment Type 8
Cesca Therapeutics Inc Pipeline Products by Development Stage 11
Cesca Therapeutics Inc Ongoing Clinical Trials by Trial Status 13

Cesca Therapeutics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Cesca Therapeutics Inc Company Profile is a detailed strategic and analytical report on Cesca Therapeutics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Cesca Therapeutics Inc (KOOL) - Product Pipeline Analysis, 2017 Update

Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine. Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the

USD 750 View Report

Soleno Therapeutics Inc (SLNO) - Product Pipeline Analysis, 2019 Update

Soleno Therapeutics Inc (Soleno) formerly Capnia Inc is a medical equipment company that designs, develops and commercializes novel therapeutic and diagnostic products. The company provides products such as serenz, cosense,

USD 750 View Report

Endonovo Therapeutics Inc (ENDV) - Product Pipeline Analysis, 2019 Update

Endonovo Therapeutics Inc (Endonovo Therapeutics) is a commercial stage development company that offers non-invasive medical devices and equipment. The companys products include Electroceutical Therapy a FDA-Cleared for the palliative treatment

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available